热景生物
(688068)
| 流通市值：159.81亿 | | | 总市值：159.81亿 |
| 流通股本：9270.79万 | | | 总股本：9270.79万 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 309,709,122.21 | 203,913,314.33 | 93,241,595.44 | 510,900,037.23 |
| 营业收入 | 309,709,122.21 | 203,913,314.33 | 93,241,595.44 | 510,900,037.23 |
| 二、营业总成本 | 421,420,697.99 | 272,195,683.45 | 130,399,057.32 | 611,500,124.43 |
| 营业成本 | 139,285,557.79 | 89,356,506.62 | 49,168,539.61 | 228,067,900.41 |
| 税金及附加 | 3,783,668.4 | 2,649,494.05 | 636,531.31 | 6,163,442.99 |
| 销售费用 | 151,132,777.93 | 91,717,894.9 | 43,441,584.85 | 191,570,764.78 |
| 管理费用 | 75,717,473.1 | 51,349,962.59 | 24,107,192.49 | 103,896,662.78 |
| 研发费用 | 67,477,321.52 | 47,825,469.82 | 20,426,393.23 | 113,311,176.16 |
| 财务费用 | -15,976,100.74 | -10,703,644.53 | -7,381,184.17 | -31,509,822.69 |
| 其中:利息费用 | 841,824.81 | 552,162.43 | - | 449,066.76 |
| 其中:利息收入 | 17,652,085.27 | 10,799,409.56 | 7,475,391.29 | 32,848,354.88 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -32,229,587.25 | -46,822,376.48 | -23,053,551.7 | 2,493,695.02 |
| 加:投资收益 | 28,465,336.44 | 20,342,884.41 | 33,698,955.39 | -11,857,198.21 |
| 资产处置收益 | 197,500.76 | 601,429.66 | -1,182.67 | -1,632,972.55 |
| 资产减值损失(新) | 161,560.18 | -21,105.85 | -25,220.12 | -83,123,913.7 |
| 信用减值损失(新) | -3,494,475.84 | -3,460,036.36 | - | -1,018,888.62 |
| 其他收益 | 6,910,202.22 | 6,894,195.87 | 2,512,018.09 | 10,149,543.59 |
| 四、营业利润 | -111,701,039.27 | -90,747,377.87 | -24,026,442.89 | -185,589,821.67 |
| 加:营业外收入 | 1,427,800.76 | 78,460.61 | 311,048.22 | 325,388.43 |
| 减:营业外支出 | 1,865,805.59 | 553,029.98 | 393,836.35 | 2,609,244.45 |
| 五、利润总额 | -112,139,044.1 | -91,221,947.24 | -24,109,231.02 | -187,873,677.69 |
| 减:所得税费用 | -1,657,432.61 | -6,250,702.73 | 457,539.02 | 8,064,976.66 |
| 六、净利润 | -110,481,611.5 | -84,971,244.51 | -24,566,770.04 | -195,938,654.35 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -110,481,611.5 | -84,971,244.51 | -24,566,770.04 | -195,938,654.35 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -108,959,463.59 | -83,997,815.68 | -24,008,215.62 | -191,004,566.74 |
| 少数股东损益 | -1,522,147.91 | -973,428.83 | -558,554.42 | -4,934,087.61 |
| 扣除非经常损益后的净利润 | -148,262,814.44 | -90,047,791.34 | -40,816,815.88 | -231,189,791.32 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -1.23 | -0.93 | -0.26 | -2.12 |
| (二)稀释每股收益 | -1.23 | -0.93 | -0.26 | -2.12 |
| 八、其他综合收益 | 5,114,949.56 | 3,646,322.15 | 317,437.68 | 5,643,061.05 |
| 归属于母公司股东的其他综合收益 | 5,102,943.23 | 3,643,757.9 | 314,276.7 | 5,641,832.25 |
| 九、综合收益总额 | -105,366,661.94 | -81,324,922.36 | -24,249,332.36 | -190,295,593.3 |
| 归属于母公司股东的综合收益总额 | -103,856,520.36 | -80,354,057.78 | -23,693,938.92 | -185,362,734.49 |
| 归属于少数股东的综合收益总额 | -1,510,141.58 | -970,864.58 | -555,393.44 | -4,932,858.81 |
| 公告日期 | 2025-10-24 | 2025-08-30 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |